Suche
Mein Konto
Evotec's shares appear to be stabilizing after a difficult start to the year and have recorded significant price gains in the last few days. This is due, among other things, to positive news from the subsidiary Just – Evotec Biologics.
Just – Evotec Biologics has expanded its collaboration with ABL, a contract developer and manufacturer serving the US government and the biopharmaceutical industry. This expansion comes under a new contract awarded by various U.S. government entities. The financial details of the agreement were not further explained.
The new agreement builds on previous collaborations between Just – Evotec Biologics and ABL, which aimed to develop efficient manufacturing processes for broadly neutralizing antibodies against HIV. The expanded agreement will see the development of a third antibody and large-scale manufacturing campaigns.